Tarsus Pharmaceuticals, Inc.

NasdaqGS TARS

Tarsus Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

Tarsus Pharmaceuticals, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Tarsus Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -5.63 M, a -762.02% change year over year.
  • Tarsus Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -653.00 K, a -3.16% change year over year.
  • Tarsus Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -633.00 K.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
SV Wall Street
NasdaqGS: TARS

Tarsus Pharmaceuticals, Inc.

CEO Dr. Bobak R. Azamian M.D.
IPO Date Oct. 16, 2020
Location United States
Headquarters 15440 Laguna Canyon Road
Employees 244
Sector Healthcare
Industries
Description

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Similar companies

IKNA

Ikena Oncology, Inc.

USD 1.46

2.82%

PEPG

PepGen Inc.

USD 1.34

7.20%

GLUE

Monte Rosa Therapeutics, Inc.

USD 6.84

2.55%

CNTA

Centessa Pharmaceuticals plc

USD 16.92

0.06%

TRDA

Entrada Therapeutics, Inc.

USD 13.99

3.17%

ETON

Eton Pharmaceuticals, Inc.

USD 18.25

1.62%

PHVS

Pharvaris N.V.

USD 17.60

-0.73%

NUVB

Nuvation Bio Inc.

USD 2.45

1.66%

ELDN

Eledon Pharmaceuticals, Inc.

USD 4.71

0.86%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.54

4.05%

STOK

Stoke Therapeutics, Inc.

USD 12.70

0.79%

DSGN

Design Therapeutics, Inc.

USD 4.86

0.41%

TVTX

Travere Therapeutics, Inc.

USD 21.21

0.52%

ALDX

Aldeyra Therapeutics, Inc.

USD 5.71

6.73%

HOWL

Werewolf Therapeutics, Inc.

USD 1.41

0.00%

TYRA

Tyra Biosciences, Inc.

USD 13.67

0.15%

NUVL

Nuvalent, Inc.

USD 88.96

3.54%

StockViz Staff

February 6, 2025

Any question? Send us an email